文献速递前列腺癌

达罗他胺靶向恩扎卢胺耐药及突变雄激素受体

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
PubMed 文献 · Eur Urol · 2017-08-26

本文为临床前研究,评估新型雄激素受体拮抗剂达罗他胺(ODM-201)在恩扎卢胺耐药去势抵抗性前列腺癌及AR突变体中的活性。体外实验中达罗他胺显著抑制恩扎卢胺耐药MR49F细胞生长与AR转录活性,体内实验使肿瘤体积和血清PSA下降并延长小鼠生存。达罗他胺显著抑制F877L、H875Y/T878A、F877L/T878A及新发现的T878G等AR突变体转录活性。

要点

  • 达罗他胺在体外显著抑制恩扎卢胺耐药MR49F细胞生长及AR转录活性。
  • 达罗他胺使恩扎卢胺耐药MR49F移植瘤小鼠肿瘤体积和血清PSA下降并延长生存。
  • 达罗他胺显著抑制F877L、H875Y/T878A、F877L/T878A及T878G等AR突变体转录活性。

核心结论

  • 结果为进一步在恩扎卢胺耐药去势抵抗性前列腺癌中临床评估达罗他胺提供依据,尤其可联合循环肿瘤DNA检测AR突变体用于精准肿瘤学。

研究设计与样本

  • 临床前研究,采用体外恩扎卢胺耐药MR49F细胞及体内MR49F移植瘤小鼠模型,并检测CRPC患者血浆中AR突变体。

主要发现

  • 达罗他胺在体外显著抑制恩扎卢胺耐药MR49F细胞生长和AR转录活性。
  • 达罗他胺在体内使MR49F移植瘤小鼠肿瘤体积和血清PSA下降,并延长生存。
  • 达罗他胺显著抑制F877L、H875Y/T878A、F877L/T878A及既往未报道的T878G AR突变体转录活性,上述突变体使恩扎卢胺转为部分激动剂。
  • 计算机化学信息学建模从原子水平证实达罗他胺对F877L和T878G AR突变体的拮抗效应。

临床怎么用

  • 作者认为结果支持在恩扎卢胺耐药CRPC中进一步临床评估达罗他胺,尤其联合循环肿瘤DNA检测对达罗他胺敏感的AR突变体用于精准肿瘤学。

局限性

  • 本文为临床前研究,作者在患者摘要中明确数据支持达罗他胺在临床试验中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Darolutamide (ODM-201) is a novel androgen receptor (AR) antagonist with a chemical structure distinctly different from currently approved AR antagonists that targets both wild-type and mutated ligand binding domain variants to inhibit AR nuclear translocation. Here, we evaluate the activity of darolutamide in enzalutamide-resistant castration resistant prostate cancer (CRPC) as well as in AR mutants detected in patients after treatment with enzalutamide, abiraterone, or bicalutamide. Darolutamide significantly inhibited cell growth and AR transcriptional activity in enzalutamide-resistant MR49F cells in vitro, and led to decreased tumor volume and serum prostate-specific antigen levels in vivo, prolonging survival in mice bearing enzalutamide-resistant MR49F xenografts. Moreover, darolutamide inhibited the transcriptional activity of AR mutants identified in the plasma of CRPC patients progressing on traditional therapies. In particular, darolutamide significantly inhibited the transcriptional activity of the F877L, H875Y/T878A, F877L/T878A, and the previously unreported T878G AR mutants, that transform enzalutamide into a partial agonist. In silico cheminformatics computer modeling provided atomic level insights confirming darolutamide antagonist effect in F877L and T878G AR mutants. In conclusion, our results provide a rationale for further clinical evaluation of darolutamide in enzalutamide-resistant CRPC, in particular in combination with circulating tumor DNA assays that detect AR mutants sensitive to darolutamide, in a precision oncology setting. PATIENT SUMMARY: In this study we evaluated the novel drug darolutamide in preclinical models of prostate cancer. We found that darolutamide delays growth of enzalutamide-resistant prostate cancer, in particular in cells with mutated forms of the androgen receptor after previous treatment. Our data supports further evaluation of darolutamide in clinical trials.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Borgmann H, Lallous N, Ozistanbullu D, et al. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). Eur Urol. 2017. PMID: 28851578. doi:10.1016/j.eururo.2017.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。